Oncotelic Grants Lunai Bioworks Rights to Nose-to-Brain Delivery System
Oncotelic granted Lunai Bioworks worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's. Nearly 98% of small-molecule drugs fail to cross the blood-brain barrier.
Oncotelic Therapeutics Inc. (OTCQB: OTLC) has closed a strategic monetization with Lunai Bioworks, granting worldwide rights to its proprietary intranasal nose-to-brain (N2B) delivery system for biodefense and Alzheimer's disease. The deal highlights a broader industry shift toward advanced delivery platforms designed to bypass the blood-brain barrier (BBB), which prevents most therapeutics from reaching the central nervous system.
The blood-brain barrier is a highly selective membrane that protects the brain from toxins and pathogens circulating in the bloodstream. While essential for survival, it presents a formidable obstacle for therapeutic development. Scientific consensus suggests that approximately 98% of small-molecule drugs and nearly all biologics fail to penetrate the BBB effectively, making CNS drug delivery one of the most persistent challenges in pharmaceutical development. This limitation contributes to the high failure rate seen in CNS drug pipelines, where promising compounds often fail, not due to lack of efficacy but because they cannot reach their intended targets in the brain. The implications extend across a wide range of conditions, including Alzheimer's disease, Parkinson's disease and brain cancers.
The global burden of Alzheimer's disease and related dementias is increasing at an unprecedented rate. According to the World Health Organization, more than 57 million people around the world are currently living with dementia, a number expected to rise significantly in the coming decades as populations age. The Alzheimer's Association notes that many drug candidates fail during clinical trials, with one key reason being the difficulty in delivering sufficient drug concentrations to the brain, even when compounds show promise in preclinical models.
Under the terms of the agreement, Oncotelic has granted Lunai Bioworks worldwide rights to the N2B delivery system IP portfolio within defined fields, specifically biodefense medical countermeasures and Alzheimer's disease only. The company continues to evaluate additional partnerships to further monetize its portfolio while maintaining strategic control over core assets. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc., Moderna Inc., CytoDyn Inc. and Northwest Biotherapeutics Inc.
Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security. As traditional drug-delivery approaches continue to face limitations, alternative methods designed to bypass the BBB, such as those being developed by Oncotelic, are gaining increasing attention. The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies.